Front Page News
Biogen Releases New Data from Cherish and Nurture Trials
Biogen will present Phase 3 end of study SPINRAZA® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor […]
Read More ›SMA Community’s Voice Heard “Loud and Clear” at Last Week’s Patient Focused Drug Development Meeting with the FDA
On April 18, 2017, the SMA community—families, clinicians, researchers, industry and regulators—gathered for a Patient-Focused Drug Development (PFDD) Meeting with the FDA. As part of […]
Read More ›Cure SMA to Host Webinar on Spinraza Access, as List of Administration Sites is Released
On Thursday, May 4, at 1:00pm EST (10:00am PST/11:00am MST/12:00pm CST), Cure SMA will hold a webinar updating the community on the status of Spinraza […]
Read More ›The European Medicines Agency (EMA) Recommends Granting Marketing Authorization in the European Union for Spinraza
The European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union (EU) for Spinraza. The recommendation indicates that Spinraza should be […]
Read More ›Cure SMA Awards $75,000 Grant to Jean Giacomotto, PhD, University of Queensland, Australia
Cure SMA has awarded a $75,000 research grant to Jean Giacomotto, PhD, at the University of Queensland, for his project, “Zebrafish models of Spinal Muscular […]
Read More ›Cure SMA Publishes Second Journal Article on the Patient Voice
Cure SMA, along with collaborators from Biogen and the SMA Foundation, have published a paper in the journal BMC Neurology. In recent years, we’ve completed […]
Read More ›Cure SMA Awards $30,000 Grant to Remy Bordonne, PhD, CNRS-Centre National de Recherche Scientifique, France
Cure SMA has awarded a $30,000 research grant to Remy Bordonne, PhD, at CNRS-Centre National de Recherche Scientifique, for his project, “Identification of the protective […]
Read More ›Cure SMA Receives Generous Donations from Fighting for Kaiden Foundation
Cure SMA would like to thank the Fighting for Kaiden Foundation for their generous donations to our equipment pool and research programs. The foundation’s generosity […]
Read More ›Record Number of Abstracts Submitted for the 2017 SMA Researcher Meeting
Abstract submission is now closed for the 2017 SMA Researcher Meeting. We are excited to announce that we received 125 submissions, a record number. Our […]
Read More ›Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA
Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open […]
Read More ›